Authors
Deepak L Bhatt, Keith AA Fox, Werner Hacke, Peter B Berger, Henry R Black, William E Boden, Patrice Cacoub, Eric A Cohen, Mark A Creager, J Donald Easton, Marcus D Flather, Steven M Haffner, Christian W Hamm, Graeme J Hankey, S Claiborne Johnston, Koon-Hou Mak, Jean-Louis Mas, Gilles Montalescot, Thomas A Pearson, P Gabriel Steg, Steven R Steinhubl, Michael A Weber, Danielle M Brennan, Liz Fabry-Ribaudo, Joan Booth, Eric J Topol
Publication date
2006/4/20
Journal
New England Journal of Medicine
Volume
354
Issue
16
Pages
1706-1717
Publisher
Massachusetts Medical Society
Description
Background
Dual antiplatelet therapy with clopidogrel plus low-dose aspirin has not been studied in a broad population of patients at high risk for atherothrombotic events.
Methods
We randomly assigned 15,603 patients with either clinically evident cardiovascular disease or multiple risk factors to receive clopidogrel (75 mg per day) plus low-dose aspirin (75 to 162 mg per day) or placebo plus low-dose aspirin and followed them for a median of 28 months. The primary efficacy end point was a composite of myocardial infarction, stroke, or death from cardiovascular causes.
Results
The rate of the primary efficacy end point was 6.8 percent with clopidogrel plus aspirin and 7.3 percent with placebo plus aspirin (relative risk, 0.93; 95 percent confidence interval, 0.83 to 1.05; P=0.22). The respective rate of the principal secondary efficacy end point, which included hospitalizations for ischemic events, was 16.7 percent …
Total citations
Scholar articles
DL Bhatt, KAA Fox, W Hacke, PB Berger, HR Black… - New England Journal of Medicine, 2006